Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the ...

The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future clinical trials ...

DURING the past five years phenethylbiguanide, more commonly known as phenformin or DBI, has proved to be a potent hypoglycemic agent. 1 Its main use has been in the control of maturity-onset diabetes ...

BOSTON - The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future ...

Metformin and phenformin both inhibit mitochondria; however, phenformin is nearly 50 times as potent as metformin. In the study, the researchers tested phenformin as a chemotherapy agent in ...

A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.

Dublin, March 26, 2025 (GLOBE NEWSWIRE) -- The "Phenformin (CAS 114-86-3) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

The biguanides are a family of drugs with diverse clinical applications. Metformin, a widely used anti-hyperglycemic biguanide, suppresses mitochondrial respiration by inhibiting respiratory complex I ...

Researchers from the University of Dundee have shown that a drug previously used to treat Type II diabetes could potentially be used to protect against cancer. A study carried out by Professors ...

An interdisciplinary research team involving the German Center for Infection Research (DZIF) has identified two antiviral drug candidates effective against a wide range of viruses. The study ...